[The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases].
V V Stel'makhA L KovalenkoV B PopovaYu P UspenskyV G MorozovT N BelikovaVladimir RafalskiyE A AntonovaPublished in: Terapevticheskii arkhiv (2021)
Administration of Remaxol as a part of the pathogenetic therapy of patients with intrahepatic cholestasis syndrome who need hepatoprotection is justified.